Specify a stock or a cryptocurrency in the search bar to get a summary
Greenwich Lifesciences Inc
GLSIGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Address: Building 14, Stafford, TX, United States, 77477
Analytics
WallStreet Target Price
38 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLSI
Dividend Analytics GLSI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLSI
Stock Valuation GLSI
Financials GLSI
Results | 2019 | Dynamics |